KB-1201

REGN7075-hIgG4

×
Please enable JavaScript in your browser to complete this form.
45317
Home » REGN7075-hIgG4

Background of REGN7075-hIgG4

    REGN7075-is-a-novel-costimulatory-bispecific-antibody-(bsAb)-designed-to-enhance-anti-tumor-immune-responses-by-bridging-epidermal-growth-factor-receptor-(EGFR)-expressing-tumor-cells-with-CD28-positive-T-cells.-This-mechanism-aims-to-activate-T-cells-within-the-tumor-microenvironment,-potentially-turning-"cold"-tumors-into-"hot"-ones,-thereby-increasing-their-responsiveness-to-immunotherapy.

Specifications

Catalog NumberKB-1201
Antibody NameREGN7075-hIgG4
FC MuationsS228P
TargetEGFR&CD28
Species ReactivityHuman
Host Cell LineEXPICHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. 1.-A-phase-1/2-study-of-REGN7075-in-combination-with-cemiplimab-(cemi)-in-patients-(pts)-with-advanced-solid-tumors:-Efficacy-and-safety-results.
Please enable JavaScript in your browser to complete this form.